Bioxcel therapeutics announces 33% enrollment in serenity at-home pivotal phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia

Data to support potential snda submission for label expansion of igalmi ® in the home setting

BTAI Ratings Summary

BTAI Quant Ranking